Strongbridge Biopharma plc presents detailed results of the RECORLEV® phase 3 LOGIC study (levocetoconazole) for the treatment of endogenous Cushing’s syndrome at the Endocrine Society’s 2021 annual meeting (ENDO)
Nikki Haley accuses Biden of ‘snubbing’ Israel, ‘approaching’ Iran: ‘I really don’t understand the logic’
